Slingshot Insights

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

MRK

100%

INCY

100%

Additional Information

Additional Relevant Details A Phase 3 study co-funded by Incyte and Merck to study epacadostat plus pembrolizumab in first-line advanced melanoma is set to initiate in the first half of 2016. From the Q4 earnings call transcript, "During the second half of 2015, and based on response rate data emerging from the dose escalation phase of the epacadostat plus pembrolizumab trial, we [Incyte] and Merck decided to initiate a first Phase III trial of the combination in first-line advanced or metastatic melanoma. Emerging data from the dose escalation cohorts reinforce our confidence in the activity of epacadostat plus pembrolizumab in first-line melanoma, and we expect a Phase III trial to begin in the next few months."

http://seekingalpha....

Additional Relevant Details A Phase 3 study, ECHO-301, evaluating the combination of epacadostat with the anti-PD-1 antibody pembrolizumab for the first-line treatment of patients with advanced or metastatic melanoma has recently been initiated

http://www.businessw...

Catalyst

Do you think this event is important to the companies below? How will it affect their stock price?

Additional Information

Slingshot Insights Explained